Low-Dose CBCT AI Model for Interventions
Official title: Low-dose AI-reconstructed CBCT Versus Full-dose CBCT for Guidance of Interventional Procedures: a Multicenter Randomized Controlled Trial
Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT07845929 · Data updated 2026-11-12
This trial tests a low-dose CBCT AI model to guide image-guided interventional procedures for adults requiring CBCT during brain, lung, or liver interventions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1380 (estimated) |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Drugs / interventions | radiation |
| Locations | 5 sites (Hefei, Anhui and 4 other locations) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | November 30, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | September 29, 2026 |
| Trial ID | NCT07845929 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older undergoing CBCT-guided interventional procedures (brain, lung, or liver) who can provide informed consent.
✕Probably not a fit
Patients unlikely to benefit include those not undergoing CBCT-guided interventions or with conditions incompatible with the low-dose protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study compares a DeepPriorCBCT-V2 AI-assisted low-dose cone-beam CT protocol with the standard full-dose CBCT used in interventional procedures. It leverages a pre-trained neural model to preserve image quality while reducing radiation exposure. Eligible participants are adults needing CBCT-guided interventions such as cerebral angiography, lung biopsies, or liver procedures. The trial collects imaging data to assess whether the AI model maintains diagnostic and procedural adequacy at reduced radiation. Safety monitoring and informed consent are integral components of the protocol.
Why it matters
Potential benefit: If successful, patients could receive similar diagnostic and procedural quality with substantially lower radiation exposure.
How similar studies have gone: Previous work with DeepPriorCBCT and related AI-enhanced dosing has shown promise in maintaining image quality at reduced doses in thoracic imaging.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Age ≥18 years.
* Requires CBCT-guided interventional treatment or surgery (e.g., cerebral angiography, lung puncture biopsy, hepatic artery chemoembolization, or percutaneous liver biopsy) and meets operational indications.
* Can understand the study's purpose, procedures, potential risks, and benefits, and voluntarily signs a written informed consent form.
Exclusion Criteria:
* History of high-dose radiation exams or treatments.
* Known allergies or severe adverse reactions to iodine contrast agents or other relevant medications.
* Pregnant or breastfeeding women.
* Severe comorbidities or chronic diseases (e.g., severe diabetes, renal insufficiency).
* Severe mental illness or cognitive impairment preventing understanding of the study procedures or providing informed consent.
⑥ Participants are not suitable for the trial per investigator's opinion.
Where it's running
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China Recruiting -
Wuhan Union Hospital
Wuhan, Hubei, China Recruiting -
Wuhan Union Jinyin Lake Hospital
Wuhan, Hubei, China Recruiting -
Wuhan Union West Hospital
Wuhan, Hubei, China Recruiting -
Zhongda Hospital, Medical School, Southeast University
Nanjing, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Lei Chen
- Email: chan0812@126.com
- Phone: 15971480677
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
International effort to set liver CEUS image-quality standards and a rating tool
A group of experts is testing a standardized set of quality criteria and a rating tool to judge liver CEUS images.
-
Pressure-enabled delivery for liver tumors using TriNav: see how it changes tumor-to-normal liver contrast
This trial tests whether the TriNav infusion system changes how a liver tumor looks on CT compared with normal liver tissue during Y90 treatment in adults with unresectable liver tumors.
-
Pulmonary rehabilitation for people with COPD who also have heart or stroke-related vascular disease
We will test if adding a three-month pulmonary rehabilitation program to usual care helps adults with COPD who also have cardiovascular or cerebrovascular disease reduce flare-ups and improve breathing and quality of life.
-
Using a Gastric Bypass Stent to Treat Liver Fibrosis in Obese Patients
This study is testing a new stent treatment for liver fibrosis in obese patients to see if it helps improve their liver health and aids in weight loss.
-
Understanding cardiovascular risks in young adults born to hypertensive pregnancies
This study is looking at the heart health of young adults in their 20s and 30s who were born to mothers with high blood pressure during pregnancy to see if it affects their risk of heart problems later on.
-
Repository of samples for cerebrovascular disorders
This study is collecting blood, fluid, and tissue samples from people with cerebrovascular diseases and strokes to help researchers learn more about these conditions and how to improve treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.